LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Pulmonary, Cerebral, and Renal Thromboembolic Disease in a Patient with COVID-19.

    Lushina, Nadia / Kuo, John S / Shaikh, Hamza A

    Radiology

    2020  Volume 296, Issue 3, Page(s) E181–E183

    MeSH term(s) Aged, 80 and over ; Betacoronavirus ; COVID-19 ; Computed Tomography Angiography ; Coronavirus Infections/complications ; Coronavirus Infections/diagnostic imaging ; Humans ; Intracranial Embolism/diagnostic imaging ; Intracranial Embolism/virology ; Kidney/blood supply ; Kidney/diagnostic imaging ; Kidney/physiopathology ; Male ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnostic imaging ; Pulmonary Embolism/diagnostic imaging ; Pulmonary Embolism/virology ; SARS-CoV-2 ; Thromboembolism/diagnostic imaging ; Thromboembolism/virology
    Keywords covid19
    Language English
    Publishing date 2020-04-23
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 80324-8
    ISSN 1527-1315 ; 0033-8419
    ISSN (online) 1527-1315
    ISSN 0033-8419
    DOI 10.1148/radiol.2020201623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ue I Zs.106: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Outpatient video-assisted thoracoscopic thymectomy in an octogenarian.

    Lushina, Nadia / Hynes, Conor F / Marshall, M Blair

    Journal of visualized surgery

    2016  Volume 2, Page(s) 168

    Abstract: Video-assisted thoracoscopic thymectomy has gained acceptance for the treatment of small thymomas. Appropriately selected elderly patients may benefit as much as younger patients from this procedure. Specific benefits of minimally invasive surgery ... ...

    Abstract Video-assisted thoracoscopic thymectomy has gained acceptance for the treatment of small thymomas. Appropriately selected elderly patients may benefit as much as younger patients from this procedure. Specific benefits of minimally invasive surgery include shorter hospital stays, decreased complications and improved oncologic outcomes. Outpatient thoracic surgery is an established model for some procedures. In this report, we present an 80-year-old patient with an enlarging 2.5 cm thymoma who successfully underwent an outpatient right video-assisted thoracoscopic thymectomy at our institution. The patient's postoperative course was uncomplicated. He continues to do well 3 years after his surgery. To our knowledge, this is the first reported outpatient video-assisted thoracoscopic thymectomy in an octogenarian.
    Language English
    Publishing date 2016-11-30
    Publishing country China
    Document type Case Reports
    ISSN 2221-2965
    ISSN 2221-2965
    DOI 10.21037/jovs.2016.11.05
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Impact of biomarkers on clinical trial risk in breast cancer.

    Parker, Jayson L / Lushina, Nadia / Bal, Prabjot S / Petrella, Teresa / Dent, Rebecca / Lopes, Gilberto

    Breast cancer research and treatment

    2012  Volume 136, Issue 1, Page(s) 179–185

    Abstract: We determined the success rate of new drug approval by the US FDA in two breast cancer indications, one of which used a biomarker. This allowed us to assess if biomarkers improved clinical trial risk in breast cancer. We performed a retrospective ... ...

    Abstract We determined the success rate of new drug approval by the US FDA in two breast cancer indications, one of which used a biomarker. This allowed us to assess if biomarkers improved clinical trial risk in breast cancer. We performed a retrospective screening of industry-sponsored drug development programs registered on clinicaltrials.gov from 1998 to 2012 for HER2-positive patients compared to patients that had either failed or had been exposed to anthracycline or taxane, whose first phase I in this indication occurred no earlier than 1998. Compounds not registered on clinicaltrials.gov and studied exclusively outside the US were excluded. Twenty-nine drugs for HER2-positive patients and 28 drugs for anthracycline/taxane-exposed patients met our screening criteria. The overall success rate of new drug development in anthracycline/taxane patients was only 15 %, while in HER2-positive patients it was 23 %. However, HER2-targeted therapies underperformed compared to broad acting agents. The cost for clinical trial testing alone, when adjusted for the risk of failure, for HER2-positive breast cancer patients was $199 million, significantly lower than the cost of $274 million for anthracycline/taxane-experienced patients. The use of a validated biomarker, such as HER2, reduced clinical trial risk by as much as 50 % resulting in cost savings of 27 % in advanced and metastatic breast cancer. However, these data have to be evaluated in a context in which studies combining a novel drug with a novel biomarker not yet recognized by the FDA may actually increase clinical trial risk.
    MeSH term(s) Anthracyclines/therapeutic use ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/economics ; Breast Neoplasms/metabolism ; Bridged-Ring Compounds/therapeutic use ; Clinical Trials as Topic ; Cost-Benefit Analysis ; Drug Approval/economics ; Female ; Humans ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/genetics ; Retrospective Studies ; Taxoids/therapeutic use ; United States ; United States Food and Drug Administration
    Chemical Substances Anthracyclines ; Biomarkers, Tumor ; Bridged-Ring Compounds ; Taxoids ; taxane (1605-68-1) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2012-11
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 604563-7
    ISSN 1573-7217 ; 0167-6806
    ISSN (online) 1573-7217
    ISSN 0167-6806
    DOI 10.1007/s10549-012-2247-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1655: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.

    Casimiro, Mathew / Rodriguez, Olga / Pootrakul, Llana / Aventian, Maral / Lushina, Nadia / Cromelin, Caroline / Ferzli, Georgina / Johnson, Kevin / Fricke, Stanley / Diba, Fantahun / Kallakury, Bhaskar / Ohanyerenwa, Chioma / Chen, Maxine / Ostrowski, Michael / Hung, Mien-Chie / Rabbani, Shafaat A / Datar, Ram / Cote, Richard / Pestell, Richard /
    Albanese, Chris

    Cancer research

    2007  Volume 67, Issue 9, Page(s) 4364–4372

    Abstract: The receptor tyrosine kinase ErbB-2 plays an important role in the regulation of growth factor-induced signal transduction cascades in the epithelium, and ErbB-2 is frequently overexpressed in epithelial tumors. Our previous studies on clinical prostate ... ...

    Abstract The receptor tyrosine kinase ErbB-2 plays an important role in the regulation of growth factor-induced signal transduction cascades in the epithelium, and ErbB-2 is frequently overexpressed in epithelial tumors. Our previous studies on clinical prostate cancer specimens indicated that ErbB-2 expression was increased in patients undergoing hormone ablation therapy. We had also shown that the critical cell cycle regulatory gene cyclin D1 and its promoter were targets of proliferative signaling in prostate cancer cell lines, and that cyclin D1 was required for ErbB-2-induced mammary tumorigenesis. In the current studies, we found that increased ErbB-2 membrane expression correlated with increased nuclear cyclin D1 staining in clinical prostate cancer specimens, and that expression of ErbB-2 was capable of inducing cell cycle progression in human prostate cancer cell lines. We further showed that ErbB-2 induced the cyclin D1 promoter in DU145 cells, and that small interfering RNA knockdown of cyclin D1 protein levels blocked a significant proportion of the heregulin-induced cell cycle progression in LNCaP cells. Probasin promoter-targeted expression of an activated ErbB-2 isoform induced cyclin D1 expression in the mouse prostate, commensurate with prostate intraepithelial neoplasia. Together, these in vitro and in vivo studies identify cyclin D1 as a critical downstream target of ErbB-2 in the prostate epithelium, both of which are possible therapeutic targets for cancer intervention. Furthermore, our novel mouse model provides a useful platform for ongoing in vivo investigations of ErbB-2 signaling in the prostate epithelium.
    MeSH term(s) Animals ; Cell Cycle/physiology ; Cell Growth Processes/physiology ; Cell Line, Tumor ; Cyclin D1/biosynthesis ; Cyclin D1/genetics ; Epithelial Cells/pathology ; Gene Expression Regulation, Neoplastic ; Genes, bcl-1 ; Humans ; Male ; Mice ; Promoter Regions, Genetic ; Prostatic Intraepithelial Neoplasia/genetics ; Prostatic Intraepithelial Neoplasia/metabolism ; Prostatic Intraepithelial Neoplasia/pathology ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; RNA, Small Interfering/genetics ; Receptor, ErbB-2/biosynthesis
    Chemical Substances RNA, Small Interfering ; Cyclin D1 (136601-57-5) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2007-05-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-06-1898
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top